Non-Hodgkin’s Lymphoma

Epidemiology, Disease and Staging

 Haematopoietic Malignancies

Myeloproliferative Malignant
diseases Leukaemias lymphomas

chronic myeloid Acute myeloid Hodgkin’s

leukaemia leukaemia lymphoma
(CML) (AML)

Polycythemia Chronic myeloid Non-hodgkin’s

vera leukaemia lymphoma
(PV) (CML) (NHL)

Idiopathic Acute lymphatic

myelofibrosis leukaemia Burkitt's lymphoma
(MF) (ALL)
cutaneous T-cell
Essential Chronic lymphatic lymphoma (CTCL)
thrombocythemia leukaemia
(ET) (CLL)

hairy cell
leukaemia
(HCL)
 Haematopoietic Malignancies

Myeloproliferative Malignant
Leukaemias
diseases lymphomas
 Family of chronic  Neoplastic  Neoplastic
neoplastic disease of a disease of
diseases haematopoietic lymphatic tissue
precursor cell
 Due to a clonal  Originates in
disorder arising  Characterised by lymph node or
at the level of the replacement of spleen
pluripotent stem normal bone
 Hodgkin’s (15%)
cell marrow
 Characterised by  Often infiltration  non-Hodgkin’s
abnormal into other organs (85%)
proliferation of 1
 Malignant clones
or more blood cell
lines suppress normal
cell formation
The Lymphatic
System
 Lymphatic Tissue

 Lymph nodes, spleen, liver, skin and the

respiratory, GI and GTU tract
 Lymphocytes undergo further proliferation and
differentiation in lymphoid tissue
– B-lymphocytes
 tend to reside in lymph nodes & spleen
– T-lymphocytes
 tend to circulate throughout the lymphatic system
 Lymph Node - normal histology
afferent lymphatic vessel capsule

o rtex
c
x follicle (mainly B-
c ort e cells)
a
par - germinal centre
dulla - mantle zone
me

artery

efferent lymphatic vessel

vein
 Hodgkin’s Lymphoma
 15% of lymphomas
 First described by Thomas Hodgkin in 1832
 Originally had a very poor prognosis
(<10% survival at 5 years)
 Improved staging techniques and understanding
of the pattern of spread helps direct
management
 Now curable in over 70% of cases through the
use of radiotherapy and chemotherapy
 Non-Hodgkin’s Lymphoma (NHL):
Definition and Indication

A heterogeneous group of B- and T-cell

malignancies that are diverse in cellular origin,
morphology, cytogenetic abnormalities, response to
treatment, and prognosis
 Non-Hodgkin’s Lymphoma (NHL)

 85% of lymphomas
 6th major cause of cancer deaths yearly
Heterogeneous group of malignant diseases
arising from lymphoid tissue
– lymph nodes, spleen
 Various immune cell types
– principally B-cells derivation (>85%)
– T-cells derivation
– Histiocytes (very rarely)
– Various stages of differentiation and maturation
 NHL Incidence

 Incidence of 13.3/100,000 per year (Aust)

 Predominates in the 40-70 years age group
– most common neoplasm in the 20-40 age group
 Incidence is rising
– 150% growth over the past 30 years
– increasing by 4% annually since 1970’s

 Mortality rate is also rising

– 2% rise per year
– third highest rise, exceeded only by lung cancer in women
and malignant melanoma
 NHL Incidence

 Increases with age

– implications
 Slight male predominance overall
 Striking male predominance for several subtypes
 Incidence of certain subtypes varies greatly
around the world
– Burkitt’s Lymphoma in African children
– T-cell type more common in Japan
 Estimated Incidence of NHL
in the Year 2000 (Worldwide)

North America
South Central Asia
Eastern Europe
Southeast Asia
Northern Europe
Western Africa
Northern Africa
Australia/New Zealand
Caribbean
Melanesia
Micronesia

0 10,000 20,000 30,000 40,000 50,000 60,000

 Estimated Incidence of NHL (US)

60,000
Estimated Annual Incidence

45,000

30,000
~4% compound annual
increase in incidence

15,000

0
1980 1985 1990 1995 2000
Year

Adapted from Greenlee et al. CA Cancer J Clin. 2001;51:15.

 Revised European-American Lymphoma
(REAL) Classification: B-Cell Neoplasms
Indolent Aggressive Very Aggressive
 CLL/SLL  PLL  Precursor
 Lymphoplasmacytic/  Plasmacytoma/ Multiple B-lymphoblastic
IMC/WM myeloma lymphoma/ Leukemia
 HCL  MCL  Burkitt’s lymphoma/
B-cell acute leukemia
 Splenic marginal zone  Follicle centre lymphoma,
 Plasma cell leukemia
lymphoma follicular, grade III
 MZL  DLCL
- Extranodal (MALT)  Primary mediastinal large
- Nodal B-cell lymphoma
 Follicle center  High-grade B-cell
lymphoma, follicular, lymphoma/Burkitt’s-like
grade I-II

Hiddemann. Blood. 1996;88:4085.

 World Health Organization (WHO)
Classification of Lymphoid Neoplasms: B-Cell
Neoplasms
 Precursor B-cell neoplasm  FL
– Precursor B-lymphoblastic – Grade 1, 0-5 centroblasts/hpf
leukemia/lymphoma (precursor B- – Grade 2, 6-15 centroblasts/hpf
cell acute lymphoblastic leukemia)
– Grade 3, >15 centroblasts/hpf
 Mature (peripheral) B-cell
 3a, >15 centroblasts, but centrocytes
neoplasms still present
– B-cell CLL/SLL  3b, centroblasts from solid sheets with
– B-cell PLL no residual centrocytes
– Lymphoplasmacytic lymphoma – Variants
– Plasmacytoma, plasma cell  Cutaneous follicle center
myeloma
 MCL
– HCL
 DLCL
 Marginal zone B-cell lymphoma
– Mediastinal (thymic) large B-cell
– Marginal zone B-cell lymphoma of lymphoma
MALT
– Intravascular lymphoma
– Nodal marginal zone lymphoma
(+/- monocytoid B-cells) – Primary effusion lymphoma
– Splenic marginal zone B-cell  Burkitt’s lymphoma/Burkitt cell
lymphoma leukemia
Jaffe et al. Ann Oncol. 1998;9 (suppl 5):S25.
 Modified Ann Arbor Staging of NHL

Stage I Involvement of a single lymph node region

Stage II Involvement of ≥ 2 lymph node regions on the same

side of the diaphragm

Stage III Involvement of lymph node regions on both sides

of the diaphragm

Stage IV Multifocal involvement of ≥ 1 extralymphatic sites

± associated lymph nodes or isolated extralymphatic
organ involvement with distant nodal involvement

The Non-Hodgkin’s Lymphoma Pathologic Classification Project. Cancer. 1982;49:2112.

Staging of NHL
Staging of NHL
Follicular non-Hodgkin’s Lymphoma
Classification and survival
 Classification of Indolent NHL:
International Working Formulation (IWF)

% of NHL Median
Class Patients Survival (y)
A. Small lymphocytic 3.6 5.8

B. Follicular, predominantly
small cleaved cell 22.5 7.2

C. Follicular, mixed small and large cell 7.7 5.1

D. Follicular, predominantly large cell 3.8 3.0

The Non-Hodgkin’s Lymphoma Pathologic Classification Project. Cancer. 1982;49:2112.

 Survival of Patients with Indolent Lymphoma:
The Stanford Experience, 1960-1996

100 1987-1996
1976-1986
80 1960-1975
Patients (%)

60

40

20

0
0 5 10 15 20 25 30
Year

Adapted from Horning. Semin Oncol. 1993;20(5 suppl 5):75.

SWOG Finding: New treatment options have
changed the natural history of follicular
lymphoma1
100
91%

79%
75
Overall survival (%)

69%

50

25

0 Adapted from
1974-1978 1988-1994 1998-2000 ref 1
CHOP + ProMACE – MOPP CHOP + monoclonal
non-specific + Interferon antibody therapy
immunostimulants

Impact of new treatment options on the natural history of follicular

lymphoma determined by SWOG via retrospective analysis of three
sequential treatment approaches. 1:Fisher et al Blood 2004;104 Abstract
583
 Follicular Lymphoma:
Overall Survival

100
Overall Survival (%)

80
IPI 0/1

60
IPI 2/3
40

20
P<0.001 IPI 4/5
0
0 1 2 3 4 5 6 7 8
Year

Adapted from Armitage and Weisenburger. J Clin Oncol. 1998;16:2780.

Aggressive non-Hodgkin’s
Lymphoma
Classification and Survival
 National High-Priority Lymphoma Study:
Overall survival for aggressive lymphoma

100
CHOP
m-BACOD
80 ProMACE-CytaBOM
MACOP-B
Patients (%)

60

40

20

0
0 1 2 3 4 5 6

Years After Radomization

Fisher et al. N Engl J Med. 1993;328:1002.

 International Prognostic Index (IPI)

Patients of all ages Risk Factors

Age >60 years
PS 2-4
LDH level Elevated
Extranodal involvement >1 site
Stage (Ann Arbor) III-IV

Patients ≤ 60 years (age-adjusted)

PS 2-4
LDH Elevated
Stage III-IV

Shipp. N Engl J Med. 1993;329:987.

 IPI Risk Strata

Risk
Risk Group Factors
All ages Low (L) 0-1
Low-intermediate (LI) 2
High-intermediate (HI) 3
High (H) 4-5

Age-adjusted L 0
LI 1
HI 2
H 3

Shipp. Blood. 1994;83:1165.

 IPI: Overall Survival by Risk Strata

100

75
Patients (%)

L
50
LI
HI
25

0
0 2 4 6 8 10
Year

Adapted from Shipp. N Engl J Med. 1993;329:987.

 Age-Adjusted IPI:
Overall Survival by Risk Strata

100

75 L
Patients (%)

LI
50

HI
25 H

0
0 2 4 6 8 10
Year

Adapted from Shipp. N Engl J Med. 1993;329:987.

 DLCL: Overall Survival

100

80
Patients (%)

IPI 0-1
60

40
IPI 2-3

20 IPI 4-5
P<0.001
0
0 1 2 3 4 5 6 7 8
Year

Adapted from Armitage and Weisenburger. J Clin Oncol. 1998;16:2780.